Diarra Ava, Gantois Guillaume, Lazrek Mouna, Verdier Basile, Elsermans Vincent, Zephir Hélène, Longère Benjamin, Gkizas Xristos, Goeminne Céline, Lemesle Gilles, Juthier Francis, Bene Johana, Launay David, Dubois Romain, Morell-Dubois Sandrine, Vuotto Fanny, Piton Anne-Laure
Department of Internal Medicine and Clinical immunology, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille Lille, France.
Centre for Anaesthesia and Resuscitation, CHU Lille Lille, France.
Card Fail Rev. 2021 May 12;7:e09. doi: 10.15420/cfr.2020.33. eCollection 2021 Mar.
Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses - in particular, the Coxsackie B viruses - are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
肠道病毒是常见的感染源,也是最常见的中枢神经系统病毒病原体之一。肠道病毒,尤其是柯萨奇B病毒,是已知的心肌炎病因。利妥昔单抗是一种基因工程嵌合抗CD20单克隆抗体。文献中的许多报告表明,重复使用利妥昔单抗治疗后感染风险更高,包括病毒感染。然而,在利妥昔单抗治疗背景下关于肠道病毒相关性心肌炎的观察却很少。作者描述了1例视神经脊髓炎谱系障碍患者,在接受利妥昔单抗治疗后发生了严重且致命的肠道病毒相关性心肌炎,其鉴别诊断困难,需与自身免疫性或巨细胞性心肌炎相区分。该病例凸显了在心肌炎疑难病例中进行全面诊断检查的重要性,包括心内膜活检。